Background: Anticancer chemotherapy is thought to be effective by means of direct cytotoxicity on tumor cells. Alternative mechanisms of efficacy have been ascribed to several common anticancer agents, including cyclophosphamide (CTX), methotrexate (MTX), anthracyclines and taxanes, postulating an antiangiogenic activity.
Introduction
Neoangiogenesis plays a key role in tumor progression of solid neoplasm [1] [2] [3] [4] . Tumor cells may induce angiogenesis via the release of numerous growth factors, prostaglandin, etc., and by their attraction of inflammatory cells which in turn release multiple angiogenic stimuli. A number of antiangiogenic agents have been recently discovered, and some are under early clinical evaluation [5] [6] [7] . In animal models, treatment with angiogenesis inhibitors has a proven antitumor effect in vivo, and can both reduce metastases and lead to regression of primary growth by necrosis following capillary retraction [8, 9] .
There is evidence that several common anticancer agents including cyclophosphamide (CTX), doxorubicin (Adriamycin) and paclitaxel (Taxol) have antiangiogenic activity in the animal model [8, 10, 11] . Low-dose methotrexate (MTX) inhibits endothelial cell proliferation in vitro, and blocks endothelial cell growth factor-induced neovascularization in the rabbit cornea assay [10] . Cytotoxic agents including CTX and MTX [11] markedly inhibited the growth of chick embryo. It is therefore possible that conventional cytotoxic agents may exert a tumor suppressive effect through an antiangiogenic mechanism. Antiangiogenic therapy appears to be improved when administered over a long period of time without treatment interruptions. Therefore, oral therapy in doses, which would be tolerable on a long run, should be considered. Among orally available drugs for the treatment of breast cancer, significant bioavailability was demonstrated for both CTX and MTX [12, 13] .
Vascular endothelial growth factor (VEGF) is an angiogenic polypeptide that is detected in a large variety of malignant human tumors including breast, brain, lung and gastrointestinal tract cancers [14, 15] . Overexpression of VEGF increased tumor growth, angiogenesis and metastases, whereas anti-VEGF antibodies inhibited the growth of tumor xenografts [16, 17] . Moreover, growth inhibition of glioma was observed in nude mice bearing this tumor derived from cells transfected with an antisense VEGF sequence [18] . Values of VEGF demonstrated a correlation with tumor bulk. Patients with disseminated breast cancer had higher serum VEGF concentrations than those with localized cancer. In particular, VEGF was found to be abnormally elevated in the serum of more than 70% of patients with advanced breast cancer [14] . VEGF content in tumor cytosols is a predictor of relapse free survival and overall survival in primary breast cancer and it might also predict outcome after adjuvant endocrine treatment [19] .
We therefore evaluated the clinical efficacy and tolerance of low-dose, oral CTX and MTX in metastatic breast cancer patients and also the impact of this regimen upon serum VEGF values.
Patients and methods

Patient selection
Patients included in the study were required to have histologically confirmed metastatic breast carcinoma that had either progressed, or not, after a first line of chemotherapy for metastatic disease. Starting in June 1998, patients that asked for a regimen characterized by few side effects were included in the study, although they had not previously received chemotherapy for metastatic disease. Other inclusion criteria were measurable or evaluable disease, age ≤80 years, performance status Eastern Cooperative Oncology Group (ECOG) ≤3, adequate bone marrow reserve defined as white blood cells >4000 mm 3 and platelets >100 000 mm 3 , adequate renal function (serum creatinine <120 µmol/l) and hepatic function (serum bilirubin <20 µmol/l, aspartate aminotransferase <60 IU/l). Any prior hormonal therapy or chemotherapy must have been discontinued at least 4 weeks before study entry. All patients must have recovered from any prior chemotherapy, radiotherapy or surgery before study entry. Each patient included in the study gave a written informed consent.
Study evaluation and treatment
Baseline evaluation included clinical examination, chest X-ray, liver ultrasound or CT scan, bone nuclear scan (plus segmental bone radiographs when bone scans were positive), ECG, complete biochemical and hematological tests. Complete blood count was then repeated every 14 days and biochemical tests every 28 days.
Treatment was administered as follows: MTX orally at a dose of 2.5 mg bd (10 am, 5 pm) on day 1 and 2 every week and CTX orally at a dose of 50 mg/day (9 am). No antiemetic treatment was prescribed. Serum VEGF was determined at baseline and every month thereafter. Fifteen milliliters of peripheral blood were collected partly into a citrate tube, for plasmatic VEGF determination, and partly into a clot-activator tube for serum VEGF determination. As the value of serum VEGF increased during clot formation and reached a plateau after 60 min [20] the samples were allowed to clot at room temperature for 2 h and then centrifuged for 10 min at 1900 g. The aliquoted samples were then stored at -30°C until analysis was performed. VEGF was assessed by an ELISA kit (Quantikine ® , R&D Systems, Minneapolis, USA). All samples and standards were assayed in duplicate. The serum was stocked in aliquots at -30°C until analysis was performed. The samples were analyzed in duplicate by a sandwich enzyme-linked immunosorbent assay (ELISA), using a monoclonal antibody specific for VEGF 165 (Quantikine ® ). In order to evaluate possible differences in VEGF values between serum and plasma, 29 patients had a control value of VEGF in both serum and plasma for each sampling.
Side effects and response
Toxicity was evaluated according to NCI-CTG criteria by clinical and laboratory investigations. Treatment was withheld and delayed for 1 week in case of a neutrophil count <1000 mm 3 and/or platelet count <75 000 mm 3 . A 50% dose reduction in the total amount of drug administered in each cycle was prescribed after hematological recovery. In the case of a neutrophil count <1500 mm 3 but >1000 mm 3 and/or platelet count <100 000 mm 3 but >75 000 mm 3 , therapy was administered with a 50% dose reduction in the total amount of drug administered in each cycle. Re-escalation of drug doses was attempted if close monitoring was possible.
In the event of grade ≥2 anorexia, nausea, vomiting, diarrhea, stomatitis, dryness of the mouth, epigastric pain or increase in transaminases, all therapy was postponed until symptoms subsided. A 50% reduction of combined CTX and MTX therapy was performed for the next cycle, with subsequent re-escalation to full dosage if tolerated. Any other nonhematological grade 3 toxicity was managed by a 50% reduction of dosage in the next cycle, which was not commenced until full recovery had occurred.
Assessment of response was performed according to WHO criteria after every 8 weeks of therapy. Complete remission (CR) was defined as the disappearance of all known lesions on two separate measurements at least 4 weeks apart. Partial remission (PR) was defined as a reduction of each lesion by at least 50%. Stable disease (SD) was defined as a decrease of <50% or an increase of <25% with no new lesions, and progressive disease as an increase of >25% or appearance of new lesions. Overall success rate was defined as the proportion of patients who achieved CRs, PRs or SDs for at least 24 weeks. Case report forms were reviewed by an independent panel composed of two medical oncologists.
Statistical analysis
The aim of the study was to obtain at least a 25% overall success rate. With 63 patients the power to detect a difference in response rate from 10% to 30% is 98% and from 10% to 25% is 91%. Estimated curves of survival and time to progression were plotted from the first day of treatment using the Kaplan-Meier method; response duration was measured from the date of achievement of response. Confidence intervals (CI) for the response rates were calculated using exact binomial methods. Given the non-normality of VEGF distribution in our sample (Shapiro-Wilk test), the non-parametric Wilcoxon matched pairs test was applied to compare VEGF values at different assay times, while the Mann-Whitney U test was performed to compare responders and non-responders with respect to their baseline VEGF levels. Relative changes in VEGF levels were calculated as ratio of the values measured at 2 months and at baseline and compared between responders and non-responders by the MannWhitney U test. Confidence intervals for the medians were obtained using 2000 bootstrap samples. Log transformed VEGF and platelet values were used in the correlation analysis as well as to estimate the effect of VEGF in the prediction of a response using logistic regression.
Results
Sixty-four patients were enrolled between July 1997 and May 2000. From June 1998, 44 patients were enrolled, 11 of them untreated with chemotherapy for metastatic disease. One patient was considered ineligible because of failure to meet one of the eligibility criteria. All but 11 patients had previously received at least one line of chemotherapy for metastatic disease and 20 patients received at least two lines. Fiftyone patients had progressive disease at study entry. All the patients had good performance status and 10 patients were ≥70 years old (Table 1) .
Oral CTX plus MTX produced two CRs and 12 PRs, providing an objective response rate of 19.0% (95% CI 10.2% to 30.9%) in the intention-to-treat analysis of all eligible patients by peer review assessment. An additional eight patients had long-term disease stabilization [no change (NC) after 24 weeks], providing an overall success (CR + PR + NC after 24 weeks) rate of 31.7%. (95% CI 20.6% to 44.7%). Five patients among those who achieved prolonged disease stabilization had progressive disease at study entry. The characteristics of responding patients are shown in Table 2 . All but three patients were pre-treated for metastatic disease and 10 of them had progressive disease at study entry. Three responding patients previously received CTX, MTX and fluorouracil (CMF)-like chemotherapy as adjuvant therapy and one for metastatic disease. Three patients received the combination of Adriamycin and cyclophosphamide (AC) for metastatic disease with progressive disease documented during the AC treatment in one patient. The median time to response was 2.7 (95% CI 2.0 to 3.3) months and, among responding patients, the median duration of response was 6.8 (95% CI 3.7 to 9.7) months. For all 63 patients the median time to progression was 2.8 (95% CI 2.1 to 5.9) months.
Twenty-six per cent of patients were still responding after 12 months.
A total of 361 months of therapy were administered, with a median administration time per patient of 2.5 months. Only 37 (10%) of the cycles were delayed and 25 (7%) of the courses administered at reduced dosages. Reason for delay and dose reduction was mainly due to leukopenia and an increase in transaminases. Table 3 summarizes the side effects observed. Treatment was well tolerated. The most frequently encountered toxicity was grade I leukopenia, which was observed in 35% of cases. An increase in transaminase values was registered in 32 cases. Six out of nine patients that presented grade III hepatic toxicity had concomitant liver metastases. A complete recovery of function was achieved with either reduction or transient interruption of MTX.
Forty-eight patients had serum VEGF levels measured at baseline and at 2 months (Table 4) . The median VEGF level for the group of 48 patients decreased with treatment from 314.5 pg/ml (95% CI 245 to 435) at baseline to 248.5 pg/ml (95% CI 205 to 310.9) at 2 months (P <0.001, Wilcoxon matched pairs test), with a median relative change of 0.75 (95% CI 0.62 to 0.83). Among responding patients the median reduction in serum VEGF was 71.5 pg/ml (95% CI 42.5 to 130), while among non-responding patients the median reduction was 73 pg/ml (95% CI -44 to 208). There is no significant difference in the median reductions (P = 0.77). Although the reduction in VEGF was of a similar magnitude in the two subgroups of patients, the reduction was statistically significant only in the subgroup of responding patients (P <0.001) (Figure 1 ). The median relative changes in responding and non-responding patients were 0.75 (95% CI 0.63 to 0.88) and 0.83 (05% CI 0.50 to 1.11), respectively. The median baseline VEGF level did not differ between the two groups (P = 0.45, Mann-Whitney U test). In 16 patients presenting long-term response the value of VEGF at 6 months remained at lower levels than baseline, median 195 pg/ml (95% CI 96 to 355) while response was maintained. Baseline values after 2 months, and the ratio of after 2 months to baseline medians, (and 95% CI) are presented for platelets and VEGF in Table 4 . Data are shown for responders, non-responders and both groups combined. The P values shown in Table 4 are for a comparison of responders with non-responders. Platelet values were higher at baseline among patients who subsequently did not respond (P = 0.01). As shown in Table 4 a decrease in the median number of platelets was observed only for non-responding patients. The median number of platelets did not change significantly for the whole sample of patients. No significant correlation was detected between serum VEGF values and platelets at baseline [correlation coefficient (r) = 0.25, P = 0.10] or at 2 months (r = 0.14, P = 0.36). Using logistic regression analysis there is no evidence that baseline serum VEGF is associated with predicting a response (P = 0.23). The relative change in serum VEGF from baseline to 2 months is also not predictive of a response (P = 0.69).
In 29 patients for whom measurements of VEGF values in both serum and plasma for each sample were taken, a good correlation between plasma and serum levels was observed at Nausea/vomiting  47  75  13  20  3  5  ----Gastric pain  61  97  2  3  ------Mucositis  60  95  3  5  ------Transaminases  31  49  11  17  12  19  9  15 --baseline as indicated by the correlation coefficient of 0.51 (P <0.01). At baseline the median plasma level of VEGF was 29.2 pg/ml (95% CI 23.8 to 40.9) while at 2 months it was 34.8 pg/ml (95% CI 24.3 to 39.5); there was no evidence of a change in plasma VEGF from baseline to 2 months (P = 0.94) nor that there was a difference between responders and nonresponders (P = 0.17).
Discussion
A dose-related cytotoxic effect on tumor cells has been postulated as the main cause of anti-neoplastic efficacy using chemotherapy for the treatment of solid tumors. This was based mainly upon the historical development of anticancer agents tested primarily in leukemia or cell cultures. Several studies in advanced breast cancer were, therefore, aimed at increasing the dose of chemotherapeutic agents to take advantage of the steep dose-intensity effect [21] . In fact, the principle of dose intensity is supported by experimental model systems where a small increase in drug dose may result in a large addition in tumor cell kill [21] [22] [23] [24] . Bonadonna et al. first reported the favorable outcome of patients treated with adjuvant cyclophosphamide, fluorouracil and methotrexate at 5 and 10 years when given the full-dose treatment compared with those given a reduced dose [25] . The issue of dose intensity and efficient tumor kill in advanced breast cancer is even more controversial [26] [27] [28] since interactions between drugs, tumor cells, stroma, hormones (and endocrine organs), growth factors and vessels is highly complex [29] . In view of the goal of palliative treatment in this setting, it is reasonable to consider disease stabilization (i.e. NC for 24 weeks or longer) as a clinical outcome [30] . The overall success rate (CR + PR + NC for 24 weeks or longer) of 32% suggests that a meaningful percentage of patients in our study benefited from treatment with low-dose chemotherapy. The observation of a 19% response rate, using a regimen with CTX and MTX at a very low-dose level, indicates that cytotoxicity cannot possibly explain entirely the efficacy of this regimen. In fact, direct cytotoxicity of anticancer agents is expected to cause bone marrow suppression, hair loss and altered mucosal repair. Conversely, this regimen demonstrated no significant hematological side effects or hair loss. Only 21% of the patients presented a grade >1 leucopenia; 12%, grade >1 neutropenia; and 8% had some hair loss. Moreover, no significant correlation was detected between the tumor shrinkage and the most commonly used surrogate indicator of cytotoxicity, i.e. leucopenia. The absence of significant bone marrow suppression, mucositis or hair loss, usually observed with standard dose CTX (± MTX), leads to a hypothetical alternative target. One plausible explanation for cell-growth inhibition might relate to the antiangiogenic effects of CTX (and also doxorubicin but not 5-fluorouracil) as postulated by Folkman et al., based upon a neovascularization model in the mouse cornea [9] . Also, low-dose MTX inhibited endothelial cell proliferation in vitro, and inhibited neovascularization by endothelial cell growth factor in the rabbit cornea assay [10] .
We assessed a possible correlation between angiogenic pathways and efficacy of the regimen by repeated determination of VEGF concentrations in the serum of patients during treatment. Table 4 illustrates the association between VEGF levels and response. Values were elevated in all patients before treatment and no significant difference in baseline values was detected between patients who subsequently responded to the treatment and patients that subsequently failed to respond.
Recently published results indicate that VEGF in the bloodstream is transported by blood cells, including leukocytes and platelets [31, 33] , and a correlation between VEGF value and platelet number has been observed [33] . The blood cells of cancer patients contain greatly elevated amounts of this major angiogenic growth factor [32, 33] . Therefore changes in VEGF during chemotherapy might be related with chemotherapy-induced thrombocytopenia and a subsequent rebound increase in platelet numbers rather than the persistent decrease in tumor-derived VEGF [34] . Moreover the finding of lower VEGF in patients undergoing chemotherapy compared with those untreated may reflect effects that not only have an influence on platelet numbers but also on platelet volume [35] . Although a possible influence of platelet volume on VEGF values cannot be excluded in the present study, no significant change in the platelet numbers was observed and serum VEGF significantly decreased after 2 months of treatment. Conversely, in a subgroup of patients where we tested both serum and plasma concentrations of VEGF, we showed that although there is a good correlation between serum and plasmatic values, there was no evidence of a change in plasma VEGF from baseline to 2 months. The role of platelets and particularly of platelet-derived VEGF in tumor biology is obscure, but not negligible. Cancer patients frequently have elevated platelet counts and an increased platelet consumption compared with healthy individuals.
Moreover, thrombocytosis is a negative prognostic factor in some cancers, and antitumor effects and improvements in terms of survival have been observed with anticoagulation therapy [36] . Other factors may influence serum VEGF concentrations other than tumor and platelets and therefore might have influenced the results observed. Studies have found variable correlations with hormones and have variably reported changes in the levels of VEGF concentration according to the phase of the menstrual cycle [37] [38] [39] . Finally, VEGF concentrations in peripheral blood mononuclear cells have been reported in cancer patients [40] . Important aspects such as the chronic use of CTX (and MTX) should be raised for the sake of discussion, especially because the response duration might last for several months. Cyclophosphamide, given together with MTX and fluorouracil has been reported to slightly increase the incidence of leukemia [41] . Dealing with leukemic risk while discussing treatment for advanced breast cancer might be futile. However, the possible use of this regimen in the adjuvant setting might require a careful estimation of such risk. Even a year of treatment, using a cumulative CTX dose of 18 g will produce only a small increase in the risk of leukemia [41] . This figure is lower than that observed with anthracyclines, which are commonly used in the adjuvant setting [42] . Also, changes of transitional epithelium [43] and immunosuppression [44, 45] are associated with prolonged use of CTX. While instructions for an abundant fluid intake evade the former, the latter side effect might require a pause in the administration of the drug(s). We encountered neither of these.
A side issue, which is worth mentioning, relates to the personal and economical costs of this regimen. Increased attention to patients' quality of life favors the use of an active oral treatment [46] . Advanced breast cancer responsive to chemotherapy might require a treatment duration of several months in responders [47] . Subjective toxicity and frequent visits to care providers represents a significant burden in terms of personal costs to the patient. Furthermore, the utility of a treatment regimen which has an economic cost of about US$10 per month is obvious.
In conclusion, low-dose, oral CTX and MTX demonstrated significant efficacy in pre-treated metastatic breast cancer. Theoretically, treatments aimed at inhibiting angiogenesis should be chronically administered for a prolonged period. These treatments might have particular usefulness for subsets of patients with limited tumor burden, such as early breast cancer [48] . Moreover, combinations of therapy that inhibit angiogenesis plus cytotoxic therapy may be more effective than either type of therapy alone. Use of oral low-dose CTX and MTX should be investigated further as a strategy against tumor progression after standard chemotherapy in the adjuvant setting.
